DBV Technologies (DBVT) Cost of Revenue (2014 - 2026)
DBV Technologies (DBVT) reported Cost of Revenue of $4.8 million for Q1 2026, up 1500.0% year-over-year from $300000.0 in Q1 2025, and up 251.91% on a QoQ basis from $1.4 million in Q4 2025.
DBV Technologies (DBVT) has 12 years of Cost of Revenue data on file, last reported at $4.8 million in Q1 2026.
- Quarterly Cost of Revenue rose 1500.0% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 252.61% YoY) and the FY2025 annual result came in at $3.2 million, up 21.17% from the prior year.
- Cost of Revenue rose to $4.8 million in Q1 2026 per DBVT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.8 million in Q1 2026 and bottomed at -$51000.0 in Q4 2022.
- The 5-year median for Cost of Revenue is $519000.0 (2024), against an average of $868647.1.
- The widest annual swing landed in 2023, when Cost of Revenue jumped 1717.65%; it then plunged 60.42% in 2025.
- Tracing DBVT's Cost of Revenue over 5 years: stood at -$51000.0 in 2022, then jumped by 1717.65% to $825000.0 in 2023, then plunged by 52.0% to $396000.0 in 2024, then soared by 244.44% to $1.4 million in 2025, then soared by 251.91% to $4.8 million in 2026.
- Per Business Quant, the three latest DBVT Cost of Revenue figures stand at $4.8 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 4.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80 Mn |
| Mar 31, 2026 | 4.80 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 419,000.00 |
| Jun 30, 2025 | 419,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 986,000.00 |
| Jun 30, 2024 | 986,000.00 |
| Mar 31, 2024 | 758,000.00 |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | 825,000.00 |
| Dec 31, 2023 | 825,000.00 |
| Sep 30, 2023 | 663,000.00 |
| Sep 30, 2023 | 663,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Mar 31, 2023 | 434,000.00 |
| Mar 31, 2023 | 434,000.00 |
| Dec 31, 2022 | -51,000.00 |
| Dec 31, 2022 | -51,000.00 |
| Sep 30, 2022 | 159,000.00 |
| Sep 30, 2022 | 159,000.00 |
| Jun 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 464,000.00 |
| Mar 31, 2022 | 464,000.00 |
| Mar 31, 2021 | 729,000.00 |
| Mar 31, 2021 | 729,000.00 |
| Mar 31, 2020 | 7.30 Mn |
| Mar 31, 2020 | 7.30 Mn |
| Sep 30, 2019 | 13.65 Mn |
| Sep 30, 2019 | 13.65 Mn |
| Dec 31, 2018 | 12.99 Mn |
| Dec 31, 2018 | 12.99 Mn |
| Sep 30, 2018 | 12.86 Mn |
| Sep 30, 2018 | 12.86 Mn |
| Jun 30, 2016 | 6.16 Mn |
| Jun 30, 2016 | 6.16 Mn |
| Jun 30, 2015 | 101,673.00 |
| Jun 30, 2015 | 101,673.00 |
| Jun 30, 2014 | 155,931.06 |
| Jun 30, 2014 | 155,931.06 |